WSGR logoWSGR logo
Craig S. Kenesky
Associate
Patents and Innovations
New York

D212-497-7767

Download vCard
Open PDF

Dr. Craig Kenesky is an associate in the New York office of Wilson Sonsini Goodrich & Rosati. Craig applies his background in synthetic organic, medicinal, peptide, bioorganic, and computational chemistry to the prosecution of domestic and foreign patent applications, as well as due diligence, freedom to operate, portfolio development strategy, opinions, and IP counseling. Craig represents clients in numerous technology-focused industries, including the chemical, pharmaceutical, biotechnology, nanotechnology, diagnostic, neutriceutical, healthcare, process and manufacturing, energy, clean technology, biofuel, genomics, software, information technology, bioinformatics, scientific instrument, personalized medicine, and medical device sectors. He performs pre-transaction due diligence on behalf of both technology companies and venture capital groups, and he develops non-infringement and invalidity strategies for generic pharmaceutical companies.

Craig teaches a class at Weill Cornell Medical College. The class covers the business strategies and decisions involved in the founding and early-stage management of a fundable and successful biotech start-up.

Craig's doctoral research at the University of Pennsylvania focused on the total synthesis of architecturally complex anti-cancer natural products, inhibitors of HIV-1 protease, carbohydrate drugs, peptide-like biomaterials, and the computational and biochemical investigation of tubulin-drug interactions leading to cancer cell death. He also held a fellowship at Columbia University, where he developed artificial enzymes and synthetic organic nanowires.

Experience

Dr. Craig Kenesky is an associate in the New York office of Wilson Sonsini Goodrich & Rosati. Craig applies his background in synthetic organic, medicinal, peptide, bioorganic, and computational chemistry to the prosecution of domestic and foreign patent applications, as well as due diligence, freedom to operate, portfolio development strategy, opinions, and IP counseling. Craig represents clients in numerous technology-focused industries, including the chemical, pharmaceutical, biotechnology, nanotechnology, diagnostic, neutriceutical, healthcare, process and manufacturing, energy, clean technology, biofuel, genomics, software, information technology, bioinformatics, scientific instrument, personalized medicine, and medical device sectors. He performs pre-transaction due diligence on behalf of both technology companies and venture capital groups, and he develops non-infringement and invalidity strategies for generic pharmaceutical companies.

Craig teaches a class at Weill Cornell Medical College. The class covers the business strategies and decisions involved in the founding and early-stage management of a fundable and successful biotech start-up.

Craig's doctoral research at the University of Pennsylvania focused on the total synthesis of architecturally complex anti-cancer natural products, inhibitors of HIV-1 protease, carbohydrate drugs, peptide-like biomaterials, and the computational and biochemical investigation of tubulin-drug interactions leading to cancer cell death. He also held a fellowship at Columbia University, where he developed artificial enzymes and synthetic organic nanowires.

Focus Areas
Recent Insights
Client Highlights
Firm Advises Aileron on IP Matters Related to $11 Million Public Offering
On June 10, 2020, Aileron Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of its underwritten public offering of its common stock, including the exercise by the underwriter of their option to purchase an additional 1,071,149 shares at the public offering price of $1.10 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Aileron to 10,162,059 shares and increased the amount of gross proceeds to $11.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Aileron. The company expects to use the net proceeds from the offering, together with its existing cash, cash equivalents and short-term investments, to fund clinical development of ALRN-6924 as a chemoprotective agent and for working capital as well as other general corporate purposes.
Learn More
Client Highlights
Wilson Sonsini Advises on IP Matters in Celgene Acquisition of Delinia
On January 26, 2017, global pharmaceutical company Celgene Corporation and Delinia, a privately held biotechnology company developing novel therapeutics for autoimmune diseases, announced that they have entered into an agreement for the acquisition of Delinia by Celgene. Wilson Sonsini is advising Delinia on intellectual property matters related to the acquisition.
Learn More
Recent Events
Affiliated Programs
WCBA & ABCT Pitch Day
Wilson Sonsini is pleased to sponsor WCBA & ABCT’s accelerator pitch competition. Future leaders from the ABCT and WCBA accelerator programs will pitch novel therapeutics, Medical Devices, and Digital Health solutions to an audience of industry experts, investors and company leaders. Firm associate Dr. Craig Kenesky is actively involved in the program and will also be in attendance.
Learn More
Affiliated Programs
NewYorkBIO Life Science Company Showcase
NewYorkBIO has partnered with NYSE to bring together New York's financial community and emerging companies developing novel therapeutics in areas which could revolutionize patient care.
Learn More
View All
WSGR logo
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.